Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/21509
Title: Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology.
Authors: Sasadeusz, Joe;Grigg, Andrew P;Hughes, Peter D;Lee Lim, Seng;Lucas, Michaela;McColl, Geoff;McLachlan, Sue Anne;Peters, Marion G;Shackel, Nicholas;Slavin, Monica;Sundararajan, Vijaya;Thompson, Alexander;Doyle, Joseph;Rickard, James;De Cruz, Peter;Gish, Robert G;Visvanathan, Kumar
Affiliation: University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia
University of California, San Francisco, S357 Parnassus Avenue, San Francisco, CA 94143, USA
Ingham Institute, 1 Campbell Street, Liverpool, Sydney, New South Wales 2170, Australia
Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia
Department of Public Health, La Trobe University, Plenty Road, Bundoora, Victoria 3086, Australia
Burnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australia
The Alfred and Monash University, 85 Commercial Road, Melbourne, Victoria 3004, Australia
St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia
Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Victoria 3000, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
University of Queensland Oral Health Centre, 288 Herston Road, Queensland 4006, Australia
Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia
University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia
National University of Singapore, 21 Lower Kent Ridge Road, Singapore 119077, Singapore
Issue Date: Aug-2019
EDate: 2019-06-06
Citation: Clinics in liver disease 2019; 23(3): 487-492
Abstract: Current recommendations concerning hepatitis C virus (HBV) reactivation are limited, with nearly all guidelines focused on its occurrence in patients with hematological malignancies or some solid tumors, who are treated with immunosuppressive therapies. Few of the guidelines address reactivation in patients receiving immunosuppression with organ transplants or treatment with any of the many immunosuppressive agents in use today for the treatment of multiple different diseases, or in patients receiving the direct-acting antivirals used in the treatment of hepatitis C virus (HCV). This article covers the immunology of HBV reactivation, mechanisms of viral clearance, and recommendations for screening and prophylaxis.
URI: http://ahro.austin.org.au/austinjspui/handle/1/21509
DOI: 10.1016/j.cld.2019.04.009
PubMed URL: 31266622
Type: Journal Article
Review
Subjects: Adaptive
Hepatitis B immunology
Hepatitis B virus
Innate
Prophylaxis
Reactivation
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.